藥明巨諾(02126.HK)急漲23%越50天線 首款CAR-T產品獲批上市
藥明巨諾-B(02126.HK)首款自主開發CAR-T產品獲國家藥監局批准上市。該股承過去三連升勢,今天一舉突破20天及50天線(18.24元及20.3元),最高見22.5元,現報21.9元,急漲23%,成交倍增至1,078萬股,涉資2.24億元。
藥明巨諾上周五公布,國家藥品監督管理局已批准其靶向CD19的自體嵌合抗原受體T(CAR-T)細胞免疫治療產品倍諾達(瑞基奧侖賽注射液(relma-cel))的新藥上市申請。倍諾達是集團首款自主開發的CAR-T產品,用於治療經過二線或以上系統性治療後成人患者的復發或難治性大B細胞淋巴瘤(r/r LBCL),更是中國首個獲批為1類生物製品的CAR-T產品,也是全球第六款獲批CAR-T產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.